Biomedical engineers at Monash University have developed an implantable glucose sensor that can operate continuously for up to three years, potentially eliminating the need for frequent replacements that plague current continuous glucose monitors.

The device, about the size of a grain of rice, uses a novel biocompatible coating that prevents the body’s immune response from degrading sensor performance over time. That immune response, called biofouling, is the main reason current implantable sensors need replacement every few weeks or months.

Professor Mark Cook, who leads Monash’s biomedical engineering department, explained that they borrowed techniques from marine biology. “Barnacles and other marine organisms have solved the biofouling problem. We looked at how shark skin and other surfaces resist fouling and adapted those principles.”

The sensor communicates wirelessly with an external reader about the size of a smartwatch, transmitting glucose readings every five minutes. More importantly, the device doesn’t require calibration with finger-prick blood tests, addressing one of the major annoyances with current systems.

Around 1.3 million Australians have diabetes, and many use continuous glucose monitors to track blood sugar levels. Current devices like the Abbott FreeStyle Libre or Dexcom G7 require replacement every 10-14 days and cost patients anywhere from $150 to $400 per month depending on insurance coverage.

The Monash team estimates their device could reduce costs by 70-80% over a three-year period while eliminating the hassle and waste associated with frequent replacements.

Clinical trials are scheduled to begin in early 2026 with 50 participants at Alfred Health in Melbourne. If those trials succeed, the device could reach the market by late 2027, though regulatory approval from the Therapeutic Goods Administration typically takes 18-24 months.

One interesting aspect of this research is how it connects to broader trends in bioelectronic medicine. The same biofouling-resistant coating could potentially be used for other implantable devices, from cardiac monitors to neural implants.

The research received funding from the Medical Research Future Fund, which has invested heavily in biomedical device development. Australia has a reasonably strong track record in medical device innovation, with companies like Cochlear and ResMed achieving global success.

Still, translating university research into commercial products remains challenging. Many promising medical devices developed in Australian universities never make it to market because of the difficulty securing follow-on investment for clinical trials and regulatory approval.

The Monash team has already spun out a company, Glucosense Biomedical, to commercialise the technology. They’ve raised $12 million in Series A funding from Australian and international investors, though they’ll need significantly more to complete clinical trials and scale up manufacturing.

Dr. Sarah Chen, who works with Team400 advising healthtech startups on commercialisation strategy, noted that medical devices face a particularly challenging path to market. “You need clinical evidence, regulatory approval, reimbursement negotiations with insurers, and then you still need to convince doctors to prescribe your device. It’s a seven-to-ten-year process even when everything goes right.”

The glucose sensor uses an enzyme-based detection method similar to current devices, but with significant improvements in sensor stability and longevity. The team also developed new signal processing algorithms to maintain accuracy as the sensor ages.

Battery life was another engineering challenge. The device uses a rechargeable battery that charges wirelessly through the skin, similar to how some cochlear implants work. Users need to wear a charging patch for about 30 minutes every two weeks.

The research builds on decades of work in bioelectronic devices at Monash. The university’s Bionic Vision Australia project, which aimed to develop a bionic eye, didn’t achieve its original goals but generated significant expertise in biocompatible materials and implantable electronics.

That’s often how research works. Failed projects leave behind knowledge and capabilities that enable future successes.

Whether this glucose sensor achieves commercial success won’t be clear for several years. But it represents the kind of biomedical engineering innovation that Australian universities do well, combining materials science, electronics, and clinical insight to solve real-world problems.